Sandoz opens €150m manufacturing facility
September 18, 2015Manufacturing and Production Austria, BioInject, Novartis, Sandoz
Sandoz has opened a €150m state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria. Known as BioInject will result in the creation …
AstraZeneca and US Government collaborate to develop new antibiotics
September 17, 2015Research and Development AstraZeneca, Azactam, BARDA, Department of Health and Human Services, HHHS, avibactam, aztreonam
AstraZeneca has entered into a public-private partnership with the US Department of Health and Human Services to develop drugs to …
Astellas Pharma EMEA appoints new chief financial officer
September 17, 2015Sales and Marketing Astellas, Eugene Van Rensburg
Astellas Pharma Europe, Middle East and Africa has appointed Eugene Van Rensburg to the position of chief financial officer, from …
NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’
September 17, 2015Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer
NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …
PMPCA rules on multiple pharma code breaches
September 17, 2015Medical Communications, Sales and Marketing ABPI, ABPI Code, PMCPA, Prescriptions Medicine Code of Practice Authority
The industry’s code of conduct regulator has ruled on several alleged breaches of the ABPI code of pharmaceutical conduct by …
Cancer Drugs Fund ‘not sustainable in current form’
September 17, 2015CDF, Cancer Drugs Fund, Department of Health, NHS England, National Audit Office, Public Accounts Committe, Roche, avastin
The Cancer Drugs Fund has improved access to treatments, although the UK still lags behind other countries despite its ‘unsustainable’ …
Amgen joins M&A rush with deals for Dezima and Xencor
September 16, 2015Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation
Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
NICE rejects Farydak for multiple myeloma
September 16, 2015Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat
NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …
Cancers diagnosed earlier in England, but cases rise
September 16, 2015Cancer, Jeremy Hunt, Public Health England, cancer diagnosis, public health
The proportion of cancers diagnosed by GPs under the ‘two-week wait’ referral pathway rose, and late diagnoses fell, after the …
President Obama nominates Dr Robert Califf as new FDA head
September 16, 2015Manufacturing and Production, Medical Communications
US President Barack Obama has put forward Dr Robert Califf as the next commissioner of the FDA, according to a …
Sanofi’s LixiLan meets target in Phase III diabetes trial
September 16, 2015Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes
Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …
The biggest side-effect of making medicine
September 16, 2015Research and Development evergreening, intellectual property, patent
International intellectual property regulations are doing serious damage to the pharmaceutical industry and, by extension, to the health of people …
R&D firms team up to tackle antibiotic resistance
September 16, 2015Research and Development AMR, Antibiotics, Jim O'Neill, O'Neill review, antimicrobial resistance, drug development
Two companies at the centre of the UK’s R&D efforts to tackle the growing threat of resistance to antibiotics are expanding …
AstraZeneca scores positive real-world Forxiga data
September 16, 2015Research and Development AstraZeneca, EASD, European Association for the Study of Diabetes, Forxiga, dapagliflozin, exenatide, real world data, real world evidence
The real-world study of AstraZeneca’s diabetes drug Forxiga has found its use in UK patients primary care patients supports the …
GSK recalls 427,000 antibiotics after contamination scare
September 15, 2015Manufacturing and Production Bactroban, FDA, GSK, manufacturing, product recalls, production, recalls
GlaxoSmithKline has had to recall more than 427,000 tubes of creams and ointments due to potential penicillin cross-contamination and the …
Sanofi to significantly expand UK inhaler plant
September 15, 2015Manufacturing and Production Cheshire, Sanofi, manufacturing, production
Sanofi is gearing up for significant expansion of its inhaler production complex in Cheshire, England. The French pharma giant has …
AstraZeneca purchases former Amgen US facility
September 15, 2015Manufacturing and Production Amgen, AstraZeneca, US, biologics, manufacturing, production
AstraZeneca has bolstered its US presence with the purchase of a high-tech biologics manufacturing facility from pharma rival Amgen. The …
PureTech appoints Michael MacLean as chief financial officer
September 14, 2015Medical Communications, Research and Development, Sales and Marketing Michael MacLean, PureTech Health
PureTech Health has appointed Michael MacLean to the management team, as chief financial officer and executive vice president. Michael MacLean …
Counting the true cost of the Cancer Drugs Fund cuts
September 14, 2015Research and Development Cancer, Cancer Drugs Fund, NHS, clinical trials, cuts, oncology
Leading figures from the pharma industry and cancer charities reacted with dismay to the recent cuts to the Cancer Drugs …
FDA strengthens safety warning for J&J’s diabetes drug Invokana
September 14, 2015Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes
Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
